In accordance with tumor immune response principles, our research group independently designed and registered a clinical trial (registration number: ChiCTR1900026175) to investigate the efficacy of triple-modality therapy involving PD-1 inhibitors, radiotherapy, and GM-CSF in patients with advanced solid tumors. This evidence concerns the gene PDCD1 and neoplasm.